Valuation: Quest PharmaTech Inc.

Capitalization 59.2L 43.37L 36.97L 34.55L 31.79L 37Cr 66.58L 4.12Cr 1.57Cr 17Cr 1.63Cr 1.59Cr 63Cr P/E ratio 2024
-1.4x
P/E ratio 2025 -3.29x
Enterprise value 67.14L 49.2L 41.93L 39.19L 36.06L 42Cr 75.52L 4.67Cr 1.78Cr 20Cr 1.85Cr 1.81Cr 72Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
82.94%
Yield 2024 *
-
Yield 2025 -
More valuation ratios * Estimated data
Dynamic Chart
1 month-22.22%
3 months-41.67%
6 months+16.67%
Current year+16.67%
More quotes
1 week 0.03
Extreme 0.03
0.04
1 month 0.02
Extreme 0.025
0.06
Current year 0.02
Extreme 0.02
0.06
1 year 0.02
Extreme 0.015
0.06
3 years 0.02
Extreme 0.015
0.1
5 years 0.02
Extreme 0.015
0.32
10 years 0
Extreme 0
0.32
More quotes
Manager TitleAgeSince
Chief Executive Officer - 17/06/2004
Director of Finance/CFO - 01/01/2005
Director TitleAgeSince
Director/Board Member - 17/06/2004
Chairman - 05/07/2021
Director/Board Member - 05/07/2021
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
0.00%0.00%+16.67%-68.18% 43.37L
-0.56%-1.38%+10.66%-1.73% 4.95TCr
-1.85%+9.96%+3.15%+6.30% 2.89TCr
+1.37%-0.22%+69.46%+29.60% 2.85TCr
+2.07%+3.35%-19.57%-23.38% 2.81TCr
-1.00%-1.81%+27.66%-23.17% 1.27TCr
+2.22%+2.61%-52.40%-29.91% 1.17TCr
-1.81%+0.04%+26.10%+83.82% 1.07TCr
+0.92%-0.10%+16.36%-5.97% 1.03TCr
+0.64%-1.44%+76.48% - 1TCr
Average +0.17%-0.13%+17.46%-3.62% 1.9TCr
Weighted average by Cap. +0.13%+0.32%+15.77%+2.61%
See all sector performances

Financials

2024 2025
Net sales - -
Net income -30.18L -22.11L -18.85L -17.62L -16.21L -19Cr -33.95L -2.1Cr -80.08L -8.84Cr -82.94L -81.23L -32Cr -18.01L -13.2L -11.25L -10.51L -10L -11Cr -20.26L -1.25Cr -47.79L -5.28Cr -49.49L -48.47L -19Cr
Net Debt 3L 2L 2L 2L 2L 1.78Cr 3L 19.7L 8L 82.95L 8L 8L 3.02Cr 8L 6L 5L 5L 4L 5Cr 9L 55.33L 21.09L 2.33Cr 21.84L 21.39L 8.49Cr
More financial data * Estimated data
Logo Quest PharmaTech Inc.
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. It also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
Employees
-
More about the company
Date Price Change Volume
07/25/07 0.0350 $ 0.00% 5,000
04/25/04 0.0350 $ +16.67% 1,000
03/25/03 0.0300 $ 0.00% 10,000
02/25/02 0.0300 $ -14.29% 1,06,000

Delayed Quote Toronto S.E., July 07, 2025 at 11:27 pm IST

More quotes